18 results about "Duodenum length" patented technology

The invention belongs to the technical field of biology, and discloses a preparation method of an intestinal plexus patch, which comprises the following steps: killing an intestinal tract donor, fixing intestinal tissue segments of duodenum, jejunum, ileum or colon by using paraformaldehyde, and dehydrating to obtain dehydrated intestinal tissue segments; washing the dehydrated intestinal tissue section and removing mesentery, fat and Pari's lymph nodes attached to the jejunum, cutting an intestinal mass of about 4-6mm perpendicular to the intestinal tissue section, flatly laying the intestinal mass on a glass slide, dropwise adding a PBS (Phosphate Buffer Solution) of Triton X-100, fixing the intestinal mass by using a smooth surface of a pair of tweezers, stripping muscle tissues along the annular muscle direction, and drying the intestinal mass in a drying oven. The intestinal slices with intermuscular nerve plexus are obtained; finally, the intestinal piece with the intermuscular nerve plexus is cleaned, then fluorescent staining and piece sealing are conducted, and the mouse intestinal nerve plexus patch is obtained. The preparation method of the mouse intestinal nerve plexus patch has the advantages of being convenient, rapid and the like.

The invention discloses a preparation method of an intestinal canal filling temperature-sensitive gel injection for gastrointestinal anastomosis guided by an ultrasonic endoscope, and belongs to the technical field of regenerative medicine. According to the specific method, poloxamer, chitosan, polycarbophil, polyvinylpyrrolidone, iohexol and methylene blue are utilized to construct the novel intestinal canal filling temperature-sensitive gel injection. The injection can be injected into the anastomotic intestinal segment of the small intestine by using a conventional nasobiliary drainage tube which is clinically used at present, and the injection becomes viscous immediately under the action of the pH value of the small intestine after injection, so that the injection is inhibited from spreading all around. Meanwhile, the injection is quickly converted into high-strength hydrogel under the action of body temperature, and the hydrogel is adhered to small intestine mucosa to inhibit gel sliding. Therefore, the injection can form a section of gel on a target small intestine section, local immobilization filling and supporting of the target small intestine section are achieved, development can be achieved, the operation difficulty of intestinal tube puncture and stent placement in gastrointestinal anastomosis guided by an ultrasonic endoscope can be greatly reduced, the operation efficiency and the success rate are improved, and the operation cost is reduced. The dosage is less than that of normal saline which is conventionally used clinically, and the effect is better. Moreover, the gel temperature can be reduced by injecting low-temperature normal saline after the operation, so that the gel is thoroughly dissolved into a solution and discharged out of the body, and the phenomenon that the gel remains in the intestinal canal after the operation to cause obstruction is avoided. Therefore, the novel intestinal canal filling temperature-sensitive gel injection has very important clinical practical application value for gastrointestinal anastomosis guided by an ultrasonic endoscope.

The present invention relates to an artificial digestive tract tissue for training in endoscopic submucosal dissection (ESD) and a method for manufacturing the same. Specifically, the invention relates to an artificial digestive tract tissue configured to mimic the mucosal layer, submucosal layer, and muscle layer constituting the human digestive tract tissue in a multilayer structure, such that swelling occurs upon liquid injection and a color change occurs due to changes in salt concentration, and to a casting and curing-based hydrogel molding process for manufacturing the same. According to the present invention, the problems associated with existing animal tissue-based ESD training simulators can be resolved, repeated use is possible, and training tailored to the structural characteristics of specific organs (stomach, large intestine, small intestine, etc.) is possible.

The utility model discloses a kind of gastric cavity plugging catheters of gastrostomy in the medical instrument technical field, the device increases plugging balloon and sealing clamping piece, can be held by inside and outside, hold stomach wall and skin to position the device, while plugging balloon seals and isolates the puncture of stomach wall inside gastric cavity, effectively avoid gastric juice to flow out, avoid gastric juice to overflow along the puncture and cause skin burning;Positioning baffle is also increased, can be unfolded inside duodenum, positioning baffle can position nutrition tube, avoid nutrition tube to slide and separate, can also effectively block pylorus, effectively avoid enteric digestive juice to enter stomach, and do not hinder gastric juice to flow into intestine normally, and by pressure relief port and pressure relief pipe, stomach is conveniently decompressed, effectively avoid that pressure is too high and nutrition liquid is refluxed to esophagus.

A system for a bypass-like, transduodenal passage of stomach contents, comprising: a transduodenal bypass unit (BE), itself comprising a transduodenal assembly (TDG) having a tubular film (7) for the passage of stomach contents into the jejunum, and also comprising a transpyloric assembly (TPG) having a hose-like or tubular shaft component (2); a transesophageal positioning unit (PE) having a tubular shaft component (9), the outer diameter of said shaft component being smaller, at least in a distal region, than the inner diameter of the shaft component (2); and an extracorporeally controllable coupling device (KE) which selectively fixates the shaft component (2) to the shaft component (9) for coupling purposes or releases the same for decoupling purposes.

The present invention relates to the field of probiotics, in particular to an Akkermansia muciniphila MG784 for alleviating constipation, promoting defecation, improving intestinal barrier function and intestinal immunity, and its uses. The Akkermansia muciniphila MG784 provided by the present invention has the deposition number DSM 35549. The Akkermansia muciniphila MG784 provided by the present invention can increase the levels of motilin (MTL), gastrin (GAS), and acetylcholine in the gastrointestinal tract, promote intestinal peristalsis, improve the small intestine propulsion rate, and ameliorate defecation time and fecal output. Furthermore, Akkermansia muciniphila MG784 can also alleviate colonic mucosal inflammation, improve the thickness of the digestive tract muscular layer, modulate the structure of the intestinal microbiota, significantly increase the abundance of beneficial bacteria, and decrease the abundance of harmful bacteria.

The present application relates to the technical field of medicine, and in particular to a budesonide-loaded oral colon-targeted delivery system, a preparation method and application. The delivery system takes Pickering emulsion-encapsulated budesonide as the core, and is sequentially coated with a low-ester pectin-calcium ion crosslinked inner layer and a low-ester pectin-chitosan polyelectrolyte complex outer layer. The preparation process is realized by combining an emulsion template method with layer-by-layer self-assembly technology. The obtained microcapsules have a uniform spherical structure, a particle size of about 400 μm, and a double-layer three-dimensional network structure. The delivery system remains stable in the gastrointestinal environment, and only releases drugs rapidly under colon pH conditions. In vitro simulation experiments show that the drug release rate is less than 5% in the stomach / small intestine stage, and is rapidly released in the colon stage. Animal experiments confirm that the effect of treating ulcerative colitis is equivalent to that of mesalamine, while the systemic toxicity is significantly reduced, the drug retention time at the colon site is more than 24 hours, and there is no accumulation in non-target organs.

The invention discloses a method for testing the influence of magnesium potassium sulfate on the growth of weaned piglets, which comprises the steps of in-vitro simulated digestive tract test and in-vivo animal test, preparation of simulated stomach and intestine digestive juice, detection of the dissociation rate of magnesium potassium sulfate in the simulated digestive juice, selection of 216 21-day-old weaned piglets, and random division of the 216 21-day-old weaned piglets into 6 groups, and relates to the technical field of livestock breeding. According to the method for testing the influence of the magnesium potassium sulfate on the growth of the weaned piglets, the dissociation and absorption rules of potassium and magnesium ions in the magnesium potassium sulfate in duodenum, jejunum and ileum of the weaned piglets are defined through in-vitro tests, and a theoretical basis is provided for dose design of in-vivo tests.

Methods and apparatus for creating an anastomosis or fistula between the gallbladder and an adjacent organ are disclosed. First, a parent magnet, typically a permanent magnet, is deployed in the stomach, small intestine, or another organ adjacent to the gallbladder, and a mating daughter material is deployed in the gallbladder in order to create a magnet-compression anastomosis. The gallbladder may then be ablated or otherwise functionally inactivated through the anastomosis. Another aspect of the invention relates to an all-in-one surgical kit that contains all the necessary specialized tools for a surgeon to perform the procedure.

The invention discloses a bile duct millstone stent for ERCP. The bile duct millstone stent comprises a stent inner opening, anti-falling fins, a stent cylinder, stent millstone teeth, stent pore channels, stent outer fins and a stent outer opening. According to the bile duct millstone stent for ERCP, stone can be conveniently and automatically ground and discharged, after the stent bile duct is placed, under the combined action of duodenum physiologic peristalsis, bile flow and human body daily activities, the stent can generate micro-amplitude rotation and axial displacement, so that the stent millstone teeth can effectively scrape and grind common bile duct stone in contact with the stent cylinder, and the stent can be used for effectively removing the bile duct stone. The ground calculus can pass through a pore channel of the stent and is smoothly discharged into the duodenum under the flushing of bile which increases the flow rate and is generated due to the fact that the inner opening is large and the outer opening is small, the design is particularly suitable for emergency treatment of patients who suffer from bile duct calculus obstruction or cannot tolerate long-time ERCP operation, and through clinical use, the surgical instrument is convenient, rapid and flexible to use and operate, and has a wide application prospect. The problem of treatment of complex biliary calculi is effectively solved, and surgical operation safety is guaranteed.

The invention relates to the technical field of microorganisms, in particular to double-fermentation paraclostridium JN807 and application thereof in preparation of drugs for preventing and / or treating piglet diarrhea. The paraclostridium bifermentans JN807 is resistant to acid and bile salt, and the artificial gastrointestinal fluid is good in tolerance, so that the paraclostridium bifermentans JN807 can smoothly pass through the stomach and enter the small intestine to play a role. In addition, the paraclostridium bifermentans JN807 can be used for effectively inhibiting the escherichia coli capable of producing enterotoxins in vivo and in vitro; and the clostridium butyricum BNCC337239 and the clostridium butyricum BNCC337239 can synergistically improve the effect of preventing and / or treating piglet diarrhea.

This invention relates to the field of microbial technology, specifically to a double-fermented *Clostridium parahaemolyticus* JN807 and its application in the preparation of drugs for the prevention and / or treatment of diarrhea in piglets. Double-fermented *Clostridium parahaemolyticus* (JN807) Paraclostridium bifermentans JN807 is acid- and bile-resistant, and tolerates artificial gastrointestinal fluids well, thus it can easily pass through the stomach and enter the small intestine to exert its effects. Furthermore, the double-fermented *Clostridium paragallinarum* (… Paraclostridium bifermentans JN807 can effectively inhibit enterotoxin-producing Escherichia coli both in vivo and in vitro; and it can synergistically enhance the effect of preparing products for the prevention and / or treatment of piglet diarrhea with Clostridium butyricum BNCC337239.

[Problem] The purpose of the present invention is to provide a medical simulator using an upper gastrointestinal tract model, the medical simulator being capable of enabling practice of a procedure closer to actual clinical practice. [Solution] Provided is a medical simulator 10 using an upper gastrointestinal tract model 30 including an esophagus model 31, a stomach model 32, and a duodenum model 33, the medical simulator 10 comprising a shape changing unit configured to change a shape of the upper gastrointestinal tract model 30 due to rotation of a mounting table 461 on which the stomach model 32 is placed.

The present application relates to a targeted ileum delivery endotoxin sequestering agent drug and its preparation method and application, belong to the technical field of pharmaceutical preparation, the drug includes specific high molecular copolymer, the high molecular copolymer includes the three-dimensional framework of organic carbon-carbon chemical bond, and includes amino group. It is aimed at transporting high molecular chelating agent to the distal small intestine and releasing, and chelating pathogen-associated molecular patterns including endotoxin and CpG-DNA produced by intestinal microorganisms. The complex formed by the high molecular chelating agent released in the ileum and the pathogenic molecular pattern can be discharged from the digestive tract, so as to reduce the body inflammation and be used for relieving various metabolic diseases.

The application provides a mosapride citrate stomach floating preparation, a preparation method thereof and application thereof. The mosapride citrate stomach floating preparation comprises first immediate-release particles, second immediate-release particles and sustained-release particles with a mass ratio of (1-2):(1-2):(1-2). The application uses the first immediate-release particles, the second immediate-release particles and the sustained-release particles in combination, and introduces mosapride citrate co-grinding materials into the second immediate-release particles and the sustained-release particles, so that the obtained preparation has a sustained-release effect. In addition, the application introduces a gas production layer coating and a retardation layer coating into the second immediate-release particles and the sustained-release particles in sequence, so that the mosapride citrate is prepared into a stomach floating preparation, the absorption of the mosapride citrate in the stomach and the upper part of the small intestine is prolonged, the blood drug concentration is stabilized, and the frequency of taking medicine is reduced. According to tests, the mosapride citrate stomach floating preparation provided by the application can be released smoothly within 2-12 hours, and has no burst release effect.

The present invention relates to a urinary system (A) for the evacuation of the contents of the large intestine, small intestine and bladder through a stoma after colostomy, ileostomy and urethrostomy and making the involuntary evacuations that occur in the stoma voluntary, which is connected to a bottom adapter (1) attached to the skin so that it isolates the stoma in the evacuation area of the user's abdominal wall.

The present disclosure relates to a device configured to move within a body cavity, such as the gastrointestinal tract, in particular, the small intestine, and methods of using the device. The presently disclosed device may be self-driving, e.g., through the use of one or more traction-motion element, and the articulation of a tip of the device may be controlled and fine-tuned. The presently disclosed device may be used in a variety of body cavities such as a vascular body lumen, a digestive body lumen, a respiratory body lumen, or a urinary body lumen, for example, for endoscopic purposes, for delivering a substance into the body cavity, for removing a substance or tissue from the body cavity, for capturing an image of the body cavity, and / or for performing an operation of a tissue or organ using the device.

Methods of weight management for a subject are provided. Generally the methods comprising: administering an effective amount to the small intestine and / or large intestine of the subject of at least one agent that increases oxygen tension and / or redox potential and / or pH in the colon of the subject to thereby manage the weight of the subject. Also provided are compositions comprising at least one agent that increases oxygen tension and / or redox potential and / or pH, wherein the composition is formulated for delivery of an effective amount of the at least one agent to the small intestine and / or large intestine of a subject following oral administration of the composition to the subject.